Sangamo Biosciences (SGMO) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Sangamo Therapeutics Reports First Quarter 2017 Financial Results
May 10, 2017 4:01 PM EDTRICHMOND, Calif., May 10, 2017 /PRNewswire/ --Â
Company Also Separately Announced Strategic Collaboration with Pfizer for Hemophilia A Phase 1/2 Gene Therapy Program
Conference Call and Webcast at 5:00 p.m. Eastern Time Today Will Discuss Structure and Terms of Collaboration with Pfizer
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its first quarter 2017 financial results and recent accomplishments.
Recent... More
